Guest guest Posted July 8, 2010 Report Share Posted July 8, 2010 Washington Drug Letter June 28, 2010 | Vol. 42 No. 26  FDA Approves Novartis’ Tasigna for First-Line CML Indication Novartis’ oncologic Tasigna has been approved to treat chronic myeloid leukemia (CML) in the first-line setting. Halff Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.